CYP1A1 rs2470144: What Your Genotype Means
The rs2470144 polymorphism is an intronic single nucleotide polymorphism located in the CYP1A1 gene on chromosome 15. The encoded enzyme plays an essential role in phase I xenobiotic metabolism, breaking down environmental toxins and processing photoproducts generated by ultraviolet radiation in tissues such as cutaneous keratinocytes. Research links this variant to subtle differences in metabolic efficiency under environmental exposure, though current scientific evidence remains limited.
What each genotype means
Typical regulatory profile
This genotype represents the common regulatory configuration for the CYP1A1 gene. Research into this specific intronic variant suggests it may influence how your skin cells process environmental toxins or ultraviolet radiation, though the overall impact on health remains limited and requires further study. If you have concerns about skin health or environmental exposures, please discuss them with a dermatologist or healthcare provider.
This is the most common genotype in many populations of European ancestry.
Varied regulatory profile
Carrying one copy of the minor allele may slightly modify the regulatory activity of the CYP1A1 gene in cutaneous tissues. Current evidence regarding this variant is limited, and it is not considered a primary driver of disease risk on its own. You should view this as a minor genetic variation rather than a clinical indicator; consult your physician if you have specific questions about skin sensitivity or environmental health.
This heterozygous genotype is found in approximately 1 in 3 to 1 in 4 individuals of European ancestry.
Minor allele regulatory profile
This genotype indicates you carry two copies of the minor allele associated with this regulatory polymorphism. While some studies explore how this variant might influence the metabolism of xenobiotics in skin cells under ultraviolet light, the clinical significance of this specific genotype is currently limited and not well-defined. This result should not be used for medical decision-making; please consult a healthcare professional for personalized health guidance.
This genotype is less common, appearing in roughly 5-10% of individuals of European ancestry.
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs2470144 is mapped to the human cytochrome P450 family 1 subfamily A member 1 (CYP1A1) gene located on chromosome 15q24.1. This variant represents an intronic single-base substitution (commonly A/G on the genomic sequence). Because it resides in a non-coding intron rather than altering the amino acid sequence directly, researchers investigate it primarily as a regulatory or tag marker. Intronic variations in cytochrome P450 genes can influence transcriptional efficiency, alternative pre-mRNA splicing, or maintain linkage disequilibrium with other functional regulatory sequences. In cutaneous keratinocytes and epithelial tissues, regulatory elements within CYP1A1 orchestrate cellular responses to exogenous stresses, including environmental pollutants and light-induced cellular damage. While rs2470144 itself does not truncate or distort the enzyme, its position makes it a candidate modifier of gene expression levels when cellular stress signals activate the locus.
Biological Role of the CYP1A1 Enzyme
The CYP1A1 gene encodes a membrane-bound monooxygenase localized primarily to the endoplasmic reticulum, belonging to the cytochrome P450 superfamily. CYP1A1 is famous for its role in phase I xenobiotic metabolism, where it oxygenates polycyclic aromatic hydrocarbons (PAHs), planar aromatic compounds, and heterocyclic amines into more polar molecules. Beyond environmental toxins, CYP1A1 is transcriptionally regulated via the aryl hydrocarbon receptor (AhR) pathway, a critical environmental sensor. In skin keratinocytes, exposure to ultraviolet (UV) radiation triggers the formation of endogenous photoproducts, such as 6-formylindolo[3,2-b]carbazole (FICZ). FICZ binds with high affinity to the AhR, causing potent upregulation of CYP1A1. The CYP1A1 enzyme then metabolizes FICZ and related photoproducts to regulate oxidative tone and clear light-induced reactive compounds, highlighting the enzyme's role at the junction of cellular protection and oxidative stress.
Research Findings and Strength of Evidence
Scientific investigation into rs2470144 focuses on whether variable CYP1A1 activity alters tissue-level outcomes during exposure to environmental stressors such as UV light. Studies exploring cutaneous aging, photo-damage, and xenobiotic bioactivation have examined CYP1A1 polymorphisms to understand why individuals display differing susceptibilities to environmental insults. In keratinocyte models, altered CYP1A1 expression influences how rapidly photoproducts are degraded and whether downstream reactive oxygen species accumulate. However, the evidence specifically tying rs2470144 to clinical outcomes remains limited and primarily correlational. While genome-wide and candidate-gene association studies have evaluated CYP1A1 loci for environmental traits, findings for rs2470144 have not reached the definitive clinical validity required for diagnostic testing. Confounding factors, such as lifetime UV exposure, lifestyle, and high linkage disequilibrium across the CYP1A1-CYP1A2 locus, mean that rs2470144 should be interpreted strictly as an exploratory trait marker.
Population Frequency and Ancestral Patterns
The distribution of alleles for rs2470144 varies moderately across world populations. In individuals of European ancestry, the minor allele frequency is estimated to be approximately 0.20 to 0.30, meaning that heterozygosity is relatively common while homozygous minor allele carriers represent a smaller percentage of the population. As with many cytochrome P450 regulatory polymorphisms, allele frequencies and haplotype structures differ significantly across continental ancestries, including East Asian, South Asian, and African populations. Because linkage disequilibrium blocks around chromosome 15q24.1 differ between ethnic groups, the specific regulatory impact tagged by rs2470144 in one population cannot be assumed to apply uniformly to another. Large genomic registries like gnomAD and the 1000 Genomes Project document these frequency variations, underlining the importance of evaluating genetic background when analyzing pharmacogenomic and xenobiotic variants.
Clinical Considerations and What You Can Do
It is critical to understand that rs2470144 is categorized as a trait-associated research variant with limited evidence, not a medical diagnosis or disease marker. Having a particular genotype at this locus does not predict specific skin damage, cancer, or toxic reactions. Standard public health recommendations for skin protection—such as using broad-spectrum sunscreen, wearing protective clothing, and avoiding excessive ultraviolet exposure—remain paramount regardless of individual genetic markers. Furthermore, while CYP1A1 is a cytochrome P450 enzyme, this specific variant does not have actionable dosing guidelines published by groups such as the Clinical Pharmacogenetics Implementation Consortium (CPIC). Consumers should never modify prescribed drug therapies or health regimens based on direct-to-consumer data for this SNP. Anyone with questions regarding medication metabolism or dermatologic health should consult a qualified physician or pharmacist.
How common is this variant?
The minor allele frequency for rs2470144 ranges between 0.20 and 0.30 in populations of European ancestry, with varying frequencies observed across other continental groups.
Frequently asked questions
Does the rs2470144 variant in CYP1A1 cause disease?
No, rs2470144 does not directly cause any known monogenic genetic disease. It is an intronic polymorphism evaluated in research studies for modest variations in xenobiotic metabolism and cellular responses to ultraviolet radiation.
How does CYP1A1 relate to sun exposure and the skin?
When skin keratinocytes are exposed to ultraviolet light, photoproducts form that bind to the aryl hydrocarbon receptor, triggering the production of the CYP1A1 enzyme. CYP1A1 works to metabolize and clear these compounds, playing a key physiological role in cellular stress responses.
Should I change my medications based on my rs2470144 result?
No, you should never adjust prescription medications based on this variant. Authoritative pharmacogenetic bodies like CPIC do not recommend medication changes based on rs2470144. Always discuss medication management with your healthcare provider or pharmacist.
Does having the minor allele mean I need more sunscreen?
Everyone requires appropriate sun protection regardless of their genetic test results. While the variant is studied in connection with photoproduct processing in skin cells, standard dermatological precautions like sunscreen and protective clothing apply universally to minimize UV-induced damage.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2470144?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A1
Influences Phase I enzyme activity, relevant to the metabolism of xenobiotics and oncology therapy responses.
Intergenic variant near CYP1A1/CYP1A2 that regulates CYP1A2 activity, altering caffeine clearance.
This variant in the CYP1A1 gene is associated with the development of pigmented spots on the cheeks.